The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice
Open accessAbstract
Metachromatic leukodystrophy (MLD) is a demyelinating lysosomal storage disorder for which new treatments are urgently needed. We previously showed that transplantation of gene-corrected hematopoietic stem progenitor cells (HSPCs) in presymptomatic myeloablated MLD mice prevented disease manifestations. Here we show that HSC gene therapy can reverse neurological deficits and neuropathological damage in affected mice, thus correcting an overt neurological disease. The efficacy of gene therapy was dependent on and proportional to arylsulfatase A (ARSA) overexpression in the microglia progeny of transplanted HSPCs. We demonstrate a widespread enzyme distribution from these cells through the CNS and a robust cross-correction of neurons and glia in vivo. Conversely, a peripheral source of enzyme, established by transplanting ARSA-overexpressing hepatocytes from transgenic donors, failed to effectively deliver the enzyme to the CNS. These results indicate that the recruitment of gene-modified, enzyme-overexpressing microglia makes the enzyme bioavailable to the brain and makes therapeutic efficacy and disease correction attainable. Overall, our data provide a strong rationale for implementing HSPC gene therapy in MLD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355 · cited 1×
“We used as a liver transplant model the fumarylacetoacetate hydrolase–deficient (FAH-deficient) mouse (23).”
MethodSelf-citationLeimig, T., Mann, L., Martin, M. D. P., Bonten, E., Persons, D., Knowles, J., Allay, J. A., Cunningham, J., Nienhuis, A. W., Smeyne, R., et al. (2002) · Blood · doi:10.1182/blood.v99.9.3169 · Cited by 75
Cited by
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Self-citationSessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502
Self-citationMahmoudi, M., Hosseinkhani, H., Hosseinkhani, M., Boutry, S., Simchi, A., Journeay, W. S., Subramani, K., & Laurent, S. (2011) · Chemical Reviews · doi:10.1021/cr1001832 · Cited by 418
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Self-citationRecent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Fumagalli, F., Calbi, V., Natali Sora, M. G., Sessa, M., Baldoli, C., Rancoita, P. M. V., Ciotti, F., Sarzana, M., Fraschini, M., Zambon, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02017-1 · Cited by 298
Self-citationPierigè, F., Serafini, S., Rossi, L., & Magnani, M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.029 · Cited by 295
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216
Self-citationCapotondo, A., Milazzo, R., Politi, L. S., Quattrini, A., Palini, A., Plati, T., Merella, S., Nonis, A., di Serio, C., Montini, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205858109 · Cited by 200
Self-citationThe Role and Metabolism of Sulfatide in the Nervous System
Eckhardt, M. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8022-3 · Cited by 193
Gene therapy for severe combined immunodeficiency: are we there yet?
Cavazzana-Calvo, M., & Fischer, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30953 · Cited by 183
Piguet, F., Sondhi, D., Piraud, M., Fouquet, F., Hackett, N. R., Ahouansou, O., Vanier, M.-T., Bieche, I., Aubourg, P., Crystal, R. G., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.015 · Cited by 91
Gene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91
“In contrast, studies with a lentiviral vector to modify the HSC had significant impact on the MLD mice (1 3 106 cells i.v in 6-week mice; Biffi et al., 2004, 2006).”
BackgroundResultEnzyme, cell and gene‐based therapies for metachromatic leukodystrophy
Sevin, C., Aubourg, P., & Cartier, N. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0540-z · Cited by 88
“This was confirmed by a recent study that also demonstrated that HSC gene therapy could correct already-established neurological disease in ARSA-deficient mice (Biffi et al 2006).”
ResultClinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
Metadata
- Authors
- Biffi, A., Capotondo, A., Fasano, S., Carro, U. D., Marchesini, S., Azuma, H., Malaguti, M. C., Amadio, S., Brambilla, R., Grompe, M., Bordignon, C., Quattrini, A., & Naldini, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-11-01
- Volume
- 116
- Issue
- 11
- Pages
- 3070-3082
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2120584824
- Cited by
- 221
- References
- 2
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.